SCHEMBL4138523

SCHEMBL4138523

O=C(O)NCc1ccc(N2CCC[C@H](NC(=O)C34CC5CC(C3)C(O)C(C5)C4)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 3/20 0.38
CYP17A1 P05093 1/20 0.38
CYP19A1 P11511 1/20 0.38
CNR1 P21554 1/20 0.37
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
DRD2 P14416 3/20 0.37
DRD4 P21917 2/20 0.37
HSD11B1 P28845 2/20 0.37
HSD11B2 P80365 2/20 0.37
EPHX1 P07099 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PPARA Q07869 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148781 0.87 CNR1 (0.48) KMT2AALDH1A1CNR1MAPTDRD2
SCHEMBL4010313 0.87 CNR1 (0.47) MEN1KMT2AALDH1A1CNR1MAPT
SCHEMBL4005560 0.85 CNR1 (0.38) KMT2AALDH1A1CNR1MAPTDRD2
SCHEMBL5950362 0.85 CNR1 (0.38) KMT2AALDH1A1CNR1MAPTDRD2
SCHEMBL27707859 0.84 CNR1 (0.38) KMT2AALDH1A1CNR1MAPTPOLB
SCHEMBL4139878 0.83 SMN1; SMN2 (0.43) SMN1; SMN2
SCHEMBL4003108 0.83 SMN1; SMN2 (0.43) SMN1; SMN2
SCHEMBL4154534 0.83 EPHX2 (0.44) KMT2ACNR1RAB9ASMN1; SMN2
SCHEMBL4140568 0.83 EPHX1 (0.43) KMT2AHSD11B1HSD11B2EPHX1
SCHEMBL4138527 0.83 CNR1 (0.37) KMT2ACNR1DRD2HSD11B1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HPGD 51/4885MEN1 379/4885KMT2A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.